72.57

0.00% 0.00

After Hours: 72.57

Avidity Biosciences Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Avidity Biosciences Inc stock is traded at $72.57, with a volume of 1.24M. It is up +0.00% in the last 24 hours and up +0.58% over the past month. Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Previous Close:

$72.57

Open:

$72.57

24h Volume:

1.24M

Relative Volume:

0.27

Market Cap:

$10.93B

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-20.40

EPS:

-3.5569

Net Cash Flow:

$-502.70M

1W Performance:

-0.04%

1M Performance:

+0.58%

6M Performance:

+96.77%

1Y Performance:

+122.40%

1-Day Range:

$72.44

$72.66

1-Week Range:

$72.40

$72.66

52-Week Range:

$21.51

$72.74

Avidity Biosciences Inc Stock (RNA) Company Profile

Name

Avidity Biosciences Inc

Sector

Healthcare (1111)

Industry

Biotechnology (622)

Phone

858-401-7900

Address

3020 CALLAN ROAD, SAN DIEGO, CA

Employee

391

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Avidity Biosciences Inc	72.57	10.93B	10.73M	-455.74M	-502.70M	-3.5569
VRTX Vertex Pharmaceuticals Inc	469.90	120.69B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.45	78.77B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	840.50	52.46B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	338.06	45.82B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	340.38	38.73B	4.98B	69.59M	525.67M	0.5197

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Avidity Biosciences Inc Stock (RNA) Latest News

Jan 30, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO - Benzinga

Jan 30, 2026

Avidity Biosciences Sets February Vote on $72-per-Share Novartis Takeover and Cardiology Spin-Off - TipRanks

Jan 30, 2026

Jan 29, 2026

Risk Recap: Whats the fair value of Avidity Biosciences Inc stock2025 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn

Jan 29, 2026

Price Action: Will Avidity Biosciences Inc announce a stock splitJuly 2025 Decliners & Growth Focused Stock Reports - baoquankhu1.vn

Jan 29, 2026

Jan 27, 2026

EFG Asset Management North America Corp. Reduces Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat

Jan 27, 2026

Jan 26, 2026